European Court Of Justice Requests European Commission To Reconsider Dual Pricing And Parallel Trade

The European Court of Justice (ECJ) has said that EU antitrust regulators must reconsider their decision that drugmakers that prevent traders from exploiting price differences across Europe are restricting competition within the EU. BMI believes that such victories are a key part of the pharmaceutical industry's drive to maintain profit margins in Europe in the face of increasingly cost-conscious governments and the 2011-2013 patent cliff, which will have a significant impact on drug company revenues. However, the extent to which companies will be able to use dual pricing will depend on the European Commission's decision after performing the more detailed

To read the full article, please choose one of the following options: